Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2010 1
2011 6
2012 4
2013 2
2015 2
2016 2
2017 2
2018 1
2019 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.
Root AR, Cao W, Li B, LaPan P, Meade C, Sanford J, Jin M, O'Sullivan C, Cummins E, Lambert M, Sheehan AD, Ma W, Gatto S, Kerns K, Lam K, D'Antona AM, Zhu L, Brady WA, Benard S, King A, He T, Racie L, Arai M, Barrett D, Stochaj W, LaVallie ER, Apgar JR, Svenson K, Mosyak L, Yang Y, Chichili GR, Liu L, Li H, Burke S, Johnson S, Alderson R, Finlay WJJ, Lin L, Olland S, Somers W, Bonvini E, Gerber HP, May C, Moore PA, Tchistiakova L, Bloom L. Root AR, et al. Among authors: finlay wjj. Antibodies (Basel). 2016 Mar 4;5(1):6. doi: 10.3390/antib5010006. Antibodies (Basel). 2016. PMID: 31557987 Free PMC article.
Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.
Townsend S, Fennell BJ, Apgar JR, Lambert M, McDonnell B, Grant J, Wade J, Franklin E, Foy N, Ní Shúilleabháin D, Fields C, Darmanin-Sheehan A, King A, Paulsen JE, Hickling TP, Tchistiakova L, Cunningham O, Finlay WJ. Townsend S, et al. Among authors: finlay wj. Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15354-9. doi: 10.1073/pnas.1510944112. Epub 2015 Nov 30. Proc Natl Acad Sci U S A. 2015. PMID: 26621728 Free PMC article.
A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv).
Tu C, Terraube V, Tam AS, Stochaj W, Fennell BJ, Lin L, Stahl M, LaVallie ER, Somers W, Finlay WJ, Mosyak L, Bard J, Cunningham O. Tu C, et al. Among authors: finlay wj. J Biol Chem. 2016 Jan 15;291(3):1267-76. doi: 10.1074/jbc.M115.688010. Epub 2015 Oct 29. J Biol Chem. 2016. PMID: 26515064 Free PMC article.
CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.
Fennell BJ, McDonnell B, Tam AS, Chang L, Steven J, Broadbent ID, Gao H, Kieras E, Alley J, Luxenberg D, Edmonds J, Fitz LJ, Miao W, Whitters MJ, Medley QG, Guo YJ, Darmanin-Sheehan A, Autin B, Shúilleabháin DN, Cummins E, King A, Krebs MR, Grace C, Hickling TP, Boisvert A, Zhong X, McKenna M, Francis C, Olland S, Bloom L, Paulsen J, Somers W, Jensen A, Lin L, Finlay WJ, Cunningham O. Fennell BJ, et al. Among authors: finlay wj. MAbs. 2013 Nov-Dec;5(6):882-95. doi: 10.4161/mabs.26201. Epub 2013 Aug 21. MAbs. 2013. PMID: 23995618 Free PMC article.
Comprehensive interrogation of a minimalist synthetic CDR-H3 library and its ability to generate antibodies with therapeutic potential.
Mahon CM, Lambert MA, Glanville J, Wade JM, Fennell BJ, Krebs MR, Armellino D, Yang S, Liu X, O'Sullivan CM, Autin B, Oficjalska K, Bloom L, Paulsen J, Gill D, Damelin M, Cunningham O, Finlay WJ. Mahon CM, et al. Among authors: finlay wj. J Mol Biol. 2013 May 27;425(10):1712-30. doi: 10.1016/j.jmb.2013.02.015. Epub 2013 Feb 19. J Mol Biol. 2013. PMID: 23429058 Clinical Trial.
21 results